The legal library gives you easy access to the FTC’s case information and other official legal, policy, and guidance documents.
20101177: Churchill Downs Incorporated; SWG Holdings, LLC
20101171: GDF SUEZ S.A.; International Power plc
In the Matter of The Coca-Cola Company; Analysis of Agreement Containing Consent Order to Aid Public Comment
20101183: Novacap Industries III, L.P.; IPL Inc.
20101176: Summit Partners Private Equity Fund VII-A, L.P.; Great Hill Equity Partners II, L.P.
20101172: Grupo Nacional de Chocolates S.A.; Charles Stephen Fehr
20101169: Siemens Aktiengesellschaft; Republic ITS Holdings, LLC
20101168: Investor AB; Molnlycke AB
20101167: Windy City Investments Holdings, L.L.C.; U.S. Bancorp
20101161: Hewlett-Packard Company; ArcSight, Inc.
20101160: UnitedHealth Group Incorporated; A-Life Medical, Inc.
20101159: Trilantic Capital Partners IV L.P.; Fortitech, Inc.
20101138: Hechos con Amor S.A. de C.V.; TSG4 L.P.
20101137: Grupo Kuo S.A.B. de C.V.; TSG4 L.P.
20101109: CA, Inc.; Arcot Systems, Inc.
Novartis AG, In the Matter of (Alcon, Inc)
To settle FTC charges that its proposed acquisition of Alcon, Inc., would be anticompetitive, Novartis AG agreed to sell an injectable eye care drug used in cataract surgery. Novartis and Alcon are the only two U.S. providers of the class of drugs known as injectable miotics, and the FTC alleges that the acquisition would have created a monopoly in injectable miotics. The settlement requires Novartis to sell its drug Miochol-E to Bausch & Lomb, Inc.